Antiviral Research: Development of Small Compound Antivirals

Our research focuses on the development of small compound antivirals, including non-nucleoside polymerase inhibitors, TL7 agonists and nucleoside analogues to combat positive sense RNA viruses that include norovirus, feline calicivirus, hepatitis C virus, Zika virus, dengue virus, and other viruses.

In the field of virology, there is an active hunt for new, effective antivirals to treat and prevent viral infections. One drug development target is the viral RNA-dependent RNA polymerase (RdRp) because of its key role in viral replication. Using established methodologies, we have produced purified, soluble and active recombinant RdRps from many viruses, using Escherichia coli expression systems. High throughput screening (HTS) is a standard platform used to identify lead compounds for drug development. The aim of the antiviral project is to conduct HTS campaigns against the viral RdRps to identify lead compounds for potential antiviral therapies.

BABS academic responsible for this project:

Currently Active: